232 results
Page 9 of 12
6-K
gx88ixd
17 Feb 09
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by Fda
12:00am
6-K
EX-99.6
ej0dhao
8 Dec 08
Teva Draws on $1.75 Billion Bridge Financing In Connection with Pending Barr Acquisition
12:00am
6-K
EX-99.2
z9jiipt9
8 Dec 08
Teva Draws on $1.75 Billion Bridge Financing In Connection with Pending Barr Acquisition
12:00am
6-K
8b01 etufggwhe1k
5 Dec 08
Current report (foreign)
12:00am
F-3ASR
b7kztcd0pw7me3agtu
4 Dec 08
Automatic shelf registration (foreign)
12:00am
6-K
ipns3 8om
19 Nov 08
Teva Completes Enrollment In Laquinimod Phase III Clinical Trial
12:00am
F-4/A
uxyzfbbvb haulb
14 Oct 08
Registration of securities (foreign) (amended)
12:00am
6-K
7bsp2efh t2jf
16 Sep 08
Teva to Present New Treatment Data at World Congress for Multiple Sclerosis
12:00am
F-4
7jktki4
16 Sep 08
Registration of securities (foreign)
12:00am
6-K
9k0ogk 4nf9s
1 Aug 08
Current report (foreign)
12:00am
6-K
EX-2
rakc4zy r538gzgx
18 Jul 08
Report of Foreign Private Issuer
12:00am
425
EX-2.1
eb5ocy64jnod
18 Jul 08
Business combination disclosure
12:00am
6-K
57c7fspnubsdl 5a0
16 Jul 08
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
12:00am
6-K
k1tvj
30 Jun 08
Teva & Anp Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction In Disease Activity
12:00am
6-K
yyhx1n
12 May 08
Current report (foreign)
12:00am
6-K
EX-2.1
o2akd9qzfnu6 4z6ebx
3 Apr 08
Current report (foreign)
12:00am
425
EX-10.1
qzpkktsi
1 Apr 08
Business combination disclosure
12:00am